SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following a sharp decline after the company's preliminary results highlighted a shift in enterprise spending, where customers are prioritizing AI-driven server, storage, and memory hardware over traditional software and consulting services. The community is actively debating whether this movement represents a buying opportunity in a resilient blue-chip company or a broader warning signal for the software sector as enterprise budgets realign toward AI infrastructure.

SK hynix, Inc. engages in the manufacture and sale of semiconductor products. Its products include dynamic random access memory, flash memory, complementary metal oxide semiconductor image sensor, and others. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

Investors are actively debating the sustainability of SK Hynix's AI-driven growth following its recent ADR listing, with community discussion centered on extreme volatility, high-profile analyst price targets, and the impact of leveraged ETFs. Many are focused on whether this memory leader will maintain its massive demand and premium valuation or if recent price swings represent a broader correction in the semiconductor sector.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing intense selling pressure as investors react to concerns over rising debt levels and the impact of broader software sector weakness triggered by IBM's recent performance. While the community is sharply divided between those betting on an AI-driven turnaround and those frustrated by the lack of management communication, many are actively debating whether this represents a long-term entry point or a continuing breakdown.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is trending as investors digest the recent announcement of a significant 20-year data center lease, while the community intensely debates the stock's future trajectory amidst heavy short interest and shifting sentiment regarding its transition from a Bitcoin miner to an AI infrastructure player.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors aggressively position themselves ahead of the semiconductor earnings season, with the company viewed as a critical supply-chain bottleneck for global AI infrastructure. Community sentiment remains focused on whether strong EUV lithography demand and aggressive capacity expansion from major chipmakers can sustain the stock's premium valuation amidst shifting geopolitical risks and macroeconomic uncertainty.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging due to investor enthusiasm surrounding silicon photonics and its critical role in validating high-performance AI hardware. The stock remains a high-conviction momentum play, with the community actively debating whether its recent testing contract wins and hyperscale demand validate its current valuation or if volatility will drive a significant repricing.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending following the US FDA's approval of its breast cancer drug, a major milestone that has the community intensely debating whether the news is already priced in or if the stock has significant room for further growth. Traders are closely monitoring heavy institutional buying and active options flow, while simultaneously discussing the potential for a share price breakout or a correction as the market digests the long-term commercial outlook.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors weigh recent business momentum, including a billion-dollar AI compute deal, against sector-wide headwinds caused by data center permitting moratoriums. While some community members view the current volatility as an institutional accumulation opportunity based on strong fundamentals, others are concerned about regulatory risks and the sustainability of long-term demand.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors react to reports of advanced H200 AI chip shipments to licensed Chinese firms, fueling optimism despite ongoing geopolitical tensions. The community remains hyper-focused on the stock's institutional order flow, with active debates over whether current price action represents a genuine breakout supported by AI infrastructure demand or a tactical bull trap.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is facing intense community debate as the stock experiences high-volatility price swings, with skeptics pointing to ongoing litigation and insider selling as signs of a 'scam' while bulls look for breakout patterns and squeeze potential. Traders are heavily focused on technical levels and option activity, with discussions centered on whether the company's aggressive expansion and valuation can be sustained against its debt load and broader market skepticism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma 

AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.

Genmab Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The...

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating the combination of fixed duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine...

Genmab Presents Promising Epcoritamab Data In Elderly DLBCL Patients

(RTTNews) - Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are not eligible for anthracycline-based chemotherapy...

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or...

Genmab Reports Epcoritamab Benefits Across Relapsed Follicular Lymphoma Subgroups

(RTTNews) - Genmab A/S (GMAB) on Thursday presented new subgroup data from the Phase 3 EPCORE FL-1 trial showing that epcoritamab in combination with rituximab and lenalidomide (R2) delivered consistent efficacy and a manageable safety profile across multiple patient subgroups wi...

Genmab Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Genmab A/S (Nasdaq: GMAB) today announced new data from a post-hoc subgroup analysis from the pivotal Phase 3 EPCORE FL-1 trial, evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, in combination with rituximab and lenalidomide (epcoritamab + R2) in adult patients with...

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

Genmab A/S (Nasdaq: GMAB) announced today that 23 abstracts, including 20 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or published at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, from May 29-June 2...

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the twelve analysts that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and...

What is HC Wainwright's Forecast for Genmab A/S Q2 Earnings?

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Research analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for shares of Genmab A/S in a report released on Thursday, April 30th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings o...

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab - ADR

Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

GMABGenmab - ADR

Fundamentals

Latest GMAB News